Related Experiment Video

Updated: May 13, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Landmarks in hormonal therapy for prostate cancer

Bertrand Tombal, E David Crawford

    BJU International
    |March 1, 2013
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
    05:19

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

    Published on: November 7, 2025

    MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
    06:54

    MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

    Published on: September 3, 2013

    Related Experiment Videos

    Last Updated: May 13, 2026

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
    05:19

    A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

    Published on: November 7, 2025

    MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
    06:54

    MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

    Published on: September 3, 2013

    Related Concept Videos

    Disorders of the Male Reproductive System01:20

    Disorders of the Male Reproductive System

    Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
    Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...

    Articles linked to this work by shared authors, journal, and citation graph.

    Real-world treatment patterns and clinical outcomes in patients with non-muscle invasive bladder cancer: a nationwide evaluation.

    World journal of urology·2026

    EORTC 2238 DE-ESCALATE: Revisiting Intermittent Maximal Androgen Blockade in Metastatic Hormone-sensitive Prostate Cancer.

    European urology·2026

    Active surveillance for intermediate-risk prostate cancer: a systematic review and pooled analysis.

    BJU international·2026

    Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

    European urology·2026

    Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

    European journal of cancer (Oxford, England : 1990)·2026

    Beyond GnRH analogues: The renaissance of estrogens in prostate cancer management.

    The French journal of urology·2026

    Long-term oncological outcomes from a prospective cohort of patients with localised prostate cancer.

    BJU international·2026

    Trends in kidney stone disease: a 5-year update of stone management in England and Scotland.

    BJU international·2026

    Learning curve of Versius-assisted radical prostatectomy: role of prior experience and proctoring.

    BJU international·2026

    Response evaluation of neoadjuvant therapy in MIBC: clinical trial-derived evidence to guide practice.

    BJU international·2026

    Off-midline versus supraumbilical specimen extraction sites in robot-assisted radical prostatectomy.

    BJU international·2026

    Symptom-guided reduction of BCG dwell time: findings from the north-REG randomized trial.

    BJU international·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us